677 related articles for article (PubMed ID: 29684564)
1. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
Zhou Y; Othus M; Walter RB; Estey EH; Wu D; Wood BL
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1615-1620. PubMed ID: 29684564
[TBL] [Abstract][Full Text] [Related]
2. Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation.
Getta BM; Devlin SM; Levine RL; Arcila ME; Mohanty AS; Zehir A; Tallman MS; Giralt SA; Roshal M
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1064-1071. PubMed ID: 28315400
[TBL] [Abstract][Full Text] [Related]
3. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
[TBL] [Abstract][Full Text] [Related]
4. IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients.
Pulsipher MA; Carlson C; Langholz B; Wall DA; Schultz KR; Bunin N; Kirsch I; Gastier-Foster JM; Borowitz M; Desmarais C; Williamson D; Kalos M; Grupp SA
Blood; 2015 May; 125(22):3501-8. PubMed ID: 25862561
[TBL] [Abstract][Full Text] [Related]
5. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.
Thol F; Gabdoulline R; Liebich A; Klement P; Schiller J; Kandziora C; Hambach L; Stadler M; Koenecke C; Flintrop M; Pankratz M; Wichmann M; Neziri B; Büttner K; Heida B; Klesse S; Chaturvedi A; Kloos A; Göhring G; Schlegelberger B; Gaidzik VI; Bullinger L; Fiedler W; Heim A; Hamwi I; Eder M; Krauter J; Schlenk RF; Paschka P; Döhner K; Döhner H; Ganser A; Heuser M
Blood; 2018 Oct; 132(16):1703-1713. PubMed ID: 30190321
[TBL] [Abstract][Full Text] [Related]
6. Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.
Zhou Y; Othus M; Araki D; Wood BL; Radich JP; Halpern AB; Mielcarek M; Estey EH; Appelbaum FR; Walter RB
Leukemia; 2016 Jul; 30(7):1456-64. PubMed ID: 27012865
[TBL] [Abstract][Full Text] [Related]
7. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
8. Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia.
Orvain C; Wilson JA; Fang M; Sandmaier BM; Rodríguez-Arbolí E; Wood BL; Othus M; Appelbaum FR; Walter RB
Haematologica; 2023 Feb; 108(2):420-432. PubMed ID: 35924583
[TBL] [Abstract][Full Text] [Related]
9. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse.
Press RD; Eickelberg G; Froman A; Yang F; Stentz A; Flatley EM; Fan G; Lim JY; Meyers G; Maziarz RT; Cook RJ
Am J Hematol; 2019 Aug; 94(8):902-912. PubMed ID: 31124175
[TBL] [Abstract][Full Text] [Related]
10. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.
Walter RB; Gooley TA; Wood BL; Milano F; Fang M; Sorror ML; Estey EH; Salter AI; Lansverk E; Chien JW; Gopal AK; Appelbaum FR; Pagel JM
J Clin Oncol; 2011 Mar; 29(9):1190-7. PubMed ID: 21282535
[TBL] [Abstract][Full Text] [Related]
11. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.
Zhou Y; Moon A; Hoyle E; Fromm JR; Chen X; Soma L; Salipante SJ; Wood BL; Wu D
Cytometry B Clin Cytom; 2019 Jan; 96(1):67-72. PubMed ID: 30417521
[TBL] [Abstract][Full Text] [Related]
12. Measurement of minimal residual disease before and after myeloablative hematopoietic cell transplantation for acute leukemia.
Appelbaum FR
Best Pract Res Clin Haematol; 2013 Sep; 26(3):279-84. PubMed ID: 24309531
[TBL] [Abstract][Full Text] [Related]
13. Post-Transplantation Day +100 Minimal Residual Disease Detection Rather Than Mixed Chimerism Predicts Relapses after Allogeneic Stem Cell Transplantation for Intermediate-Risk Acute Myelogenous Leukemia Patients Undergoing Transplantation in Complete Remission.
Klyuchnikov E; Badbaran A; Massoud R; Fritzsche-Friedland U; Freiberger P; Ayuk F; Wolschke C; Bacher U; Kröger N
Transplant Cell Ther; 2022 Jul; 28(7):374.e1-374.e9. PubMed ID: 35429661
[TBL] [Abstract][Full Text] [Related]
14. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
[TBL] [Abstract][Full Text] [Related]
15. Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia.
Zhang YW; Su L; Tan YH; Lin H; Liu XL; Liu QJ; Sun JN; Zhang M; Du YZ; Song F; Han W; Gao SJ
Ann Hematol; 2023 Feb; 102(2):337-347. PubMed ID: 36378304
[TBL] [Abstract][Full Text] [Related]
16. Minimal residual disease assessed with deep sequencing of NPM1 mutations predicts relapse after allogeneic stem cell transplant in AML.
Delsing Malmberg E; Johansson Alm S; Nicklasson M; Lazarevic V; Ståhlman S; Samuelsson T; Lenhoff S; Asp J; Ehinger M; Palmqvist L; Brune M; Fogelstrand L
Leuk Lymphoma; 2019 Feb; 60(2):409-417. PubMed ID: 30068244
[TBL] [Abstract][Full Text] [Related]
17. Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.
Kayser S; Benner A; Thiede C; Martens U; Huber J; Stadtherr P; Janssen JW; Röllig C; Uppenkamp MJ; Bochtler T; Hegenbart U; Ehninger G; Ho AD; Dreger P; Krämer A
Blood Cancer J; 2016 Jul; 6(7):e449. PubMed ID: 27471865
[TBL] [Abstract][Full Text] [Related]
18. DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant.
Dillon LW; Gui G; Page KM; Ravindra N; Wong ZC; Andrew G; Mukherjee D; Zeger SL; El Chaer F; Spellman S; Howard A; Chen K; Auletta J; Devine SM; Jimenez Jimenez AM; De Lima MJG; Litzow MR; Kebriaei P; Saber W; Weisdorf DJ; Hourigan CS
JAMA; 2023 Mar; 329(9):745-755. PubMed ID: 36881031
[TBL] [Abstract][Full Text] [Related]
19. Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations.
Freeman SD; Hills RK; Virgo P; Khan N; Couzens S; Dillon R; Gilkes A; Upton L; Nielsen OJ; Cavenagh JD; Jones G; Khwaja A; Cahalin P; Thomas I; Grimwade D; Burnett AK; Russell NH
J Clin Oncol; 2018 May; 36(15):1486-1497. PubMed ID: 29601212
[TBL] [Abstract][Full Text] [Related]
20. Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission.
Karas M; Steinerova K; Lysak D; Hrabetova M; Jungova A; Sramek J; Jindra P; Polivka J; Holubec L
Anticancer Res; 2016 Oct; 36(10):5487-5498. PubMed ID: 27798920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
